X4 Pharmaceuticals secures up to $150 million senior debt facility with K2 HealthVentures
XFOR•X4 Pharmaceuticals entered a senior secured term loan facility of up to $150 million with K2 HealthVentures. It received $80 million at closing, repaid all obligations under its prior loan, including $75 million in principal, and may borrow up to an additional $70 million subject to approval and other conditions.
1. Loan facility details
X4 Pharmaceuticals entered a senior secured term loan facility of up to $150 million with K2 HealthVentures. The company received $80 million at closing and used it to repay all obligations under its prior loan, including $75 million in principal.
2. Additional borrowing
The facility provides for up to $70 million in additional borrowing, subject to K2 HealthVentures' approval and other conditions. It has a 48-month maturity and a longer interest-only period, and is intended to support financing runway and potential mavorixafor launch preparations.
